Anika Therapeutics, Inc. (ANIK) posted a first quarter loss from continuing operations of $3.96 million compared to a loss of $1.96 million, a year ago. Loss from continuing operations per share was $0.28 compared to a loss of $0.13. Adjusted net loss per share was $0.06 compared to profit of $0.13. Adjusted EBITDA was $0.1 million, for the quarter.
First quarter revenue from continuing operations was $26.2 million, a 10% decrease compared to the same period in 2024.
The company now expects fiscal 2025 adjusted EBITDA between a decline of 3% and an increase of 3%. Previously, the company projected growth in a range of 8% to 10%.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.